Novo Nordisk Launches Discounted Wegovy Subscriptions to Fight Back Against Eli Lilly

Novo Nordisk is making a bold move to regain market share in the booming weight-loss drug space. The company just introduced discounted self-pay subscription plans for Wegovy in the U.S., offering prices up to nearly 30% below its standard rate. New Pricing Details: Injections (Wegovy): $329/month (3-month plan) $299/month (6-month plan) $249/month (12-month plan) vs. standard price of $349/month Pills (Wegovy): $289 → $249/month depending on plan length vs. standard $299/month This comes after Novo already cut its standard self-pay price from $499 to $349 earlier. Why Novo Is Doing This To compete more aggressively with Eli Lilly’s Zepbound To win back users from cheaper compounded versions To improve long-term adherence through subscription lock-ins To shift more volume toward direct-to-...